DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis
Lukin, D, Weiss, A, Aniwan, S, Kadire, S, Tran, G, Rahal, M, Faleck, D, Winters, A, Chablaney, S, Meserve, J, Kochhar, G, Shashi, P, Koliani-Pace, J L, Bohm, M, Sagi, S V, Fischer, M, Boland, B, SinghVolume:
12
Language:
english
Journal:
Journal of Crohn's and Colitis
DOI:
10.1093/ecco-jcc/jjx180.046
Date:
January, 2018
File:
PDF, 91 KB
english, 2018